Compare BridgeBio Pharma Inc (BBIO) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Jones Lang LaSalle Inc — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Jones Lang LaSalle Inc trades at $315.67 (market cap $14.94B). The key difference: BridgeBio Pharma Inc and Jones Lang LaSalle Inc are close in size by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | JLL | |
|---|---|---|
Market Cap | $16.46B | $14.94B |
Sector | Health | Real Estate |
52-Week High | $90.17 | $358.66 |
52-Week Low | $44.81 | $248.95 |
Enterprise Value | $18.02B | $18.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
JLL trades at $321.95, down 0.77% today, with a bullish technical outlook supported by moving averages and strong support near $319. The company shows robust fundamentals with revenue growth to $26.12B in 2025 and consistent earnings beats, while valuation ratios like P/E of 17.32 and P/S of 0.58 appear reasonable. Recent news highlights significant refinancing deals and positive AI workforce studies, reinforcing business momentum.
JLL offers a favorable risk-reward profile with a consensus price target of $405.50 implying 26% upside, backed by analyst optimism and improving cash flows. Key risks include economic sensitivity to real estate cycles and competitive pressures. The stock presents a growth opportunity driven by operational execution and market leadership, though investors should monitor debt levels and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
